Published in Proc Natl Acad Sci U S A on September 25, 2002
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
Sequence determinants of amyloid fibril formation. Proc Natl Acad Sci U S A (2003) 2.71
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A (2012) 2.27
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A (2004) 2.14
Folding versus aggregation: polypeptide conformations on competing pathways. Arch Biochem Biophys (2007) 1.97
The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology. Physiol Rev (2012) 1.95
Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep (2013) 1.87
Cu/Zn superoxide dismutase mutants associated with amyotrophic lateral sclerosis show enhanced formation of aggregates in vitro. Proc Natl Acad Sci U S A (2003) 1.81
Prevention of amyloid-like aggregation as a driving force of protein evolution. EMBO Rep (2007) 1.78
The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol (2012) 1.70
Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.55
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol (2013) 1.54
Altered dimer interface decreases stability in an amyloidogenic protein. J Biol Chem (2008) 1.50
Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb Perspect Biol (2011) 1.41
Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy. Biophys J (2005) 1.36
Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci U S A (2003) 1.26
Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry (2008) 1.26
Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. Am J Hum Genet (2007) 1.24
Oligomerization of amyloid Abeta16-22 peptides using hydrogen bonds and hydrophobicity forces. Biophys J (2004) 1.16
Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol (2013) 1.14
Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res (2013) 1.09
Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS). Circ Heart Fail (2010) 1.07
Intrinsic fibrillation of fast-acting insulin analogs. J Diabetes Sci Technol (2012) 1.03
Amyloid formation of a protein in the absence of initial unfolding and destabilization of the native state. Biophys J (2005) 1.03
Model discrimination and mechanistic interpretation of kinetic data in protein aggregation studies. Biophys J (2009) 1.02
A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. J Am Chem Soc (2010) 1.02
Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov (2015) 1.02
Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention. Crit Rev Biochem Mol Biol (2012) 1.01
Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem (2009) 0.99
Fibrillation precursor of superoxide dismutase 1 revealed by gradual tuning of the protein-folding equilibrium. Proc Natl Acad Sci U S A (2012) 0.98
Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. Biochemistry (2011) 0.98
Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease. Biochemistry (2005) 0.97
Characterization of the interaction of β-amyloid with transthyretin monomers and tetramers. Biochemistry (2010) 0.95
Endoplasmic reticulum quality control regulates the fate of transthyretin variants in the cell. EMBO J (2007) 0.95
The structural impact of a polyglutamine tract is location-dependent. Biophys J (2008) 0.93
Population of nonnative states of lysozyme variants drives amyloid fibril formation. J Am Chem Soc (2011) 0.93
AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci U S A (2013) 0.92
Age-related oxidative modifications of transthyretin modulate its amyloidogenicity. Biochemistry (2013) 0.92
Fourier transform infrared spectroscopy provides a fingerprint for the tetramer and for the aggregates of transthyretin. Biophys J (2006) 0.91
Mechanisms of transthyretin inhibition of β-amyloid aggregation in vitro. J Neurosci (2013) 0.91
A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers. BMC Med Genet (2010) 0.90
Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev (2015) 0.89
Stilbene vinyl sulfonamides as fluorogenic sensors of and traceless covalent kinetic stabilizers of transthyretin that prevent amyloidogenesis. J Am Chem Soc (2013) 0.89
Localized structural fluctuations promote amyloidogenic conformations in transthyretin. J Mol Biol (2013) 0.88
Aromatic sulfonyl fluorides covalently kinetically stabilize transthyretin to prevent amyloidogenesis while affording a fluorescent conjugate. J Am Chem Soc (2013) 0.88
Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS One (2009) 0.87
Initial conformational changes of human transthyretin under partially denaturing conditions. Biophys J (2005) 0.86
Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry (2014) 0.85
A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis. Neurol Ther (2015) 0.83
Current and future treatment of amyloid diseases. J Intern Med (2016) 0.83
Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid (2016) 0.82
Amyloidogenic potential of transthyretin variants: insights from structural and computational analyses. J Biol Chem (2009) 0.82
Inhibition of human transthyretin aggregation by non-steroidal anti-inflammatory compounds: a structural and thermodynamic analysis. Int J Mol Sci (2013) 0.82
ATF6 activation reduces the secretion and extracellular aggregation of destabilized variants of an amyloidogenic protein. Chem Biol (2014) 0.82
Identification and characterization of Aβ peptide interactors in Alzheimer's disease by structural approaches. Front Aging Neurosci (2014) 0.81
Considerably Unfolded Transthyretin Monomers Preceed and Exchange with Dynamically Structured Amyloid Protofibrils. Sci Rep (2015) 0.80
Simulation of pH-dependent edge strand rearrangement in human beta-2 microglobulin. Protein Sci (2005) 0.80
Bifunctional coumarin derivatives that inhibit transthyretin amyloidogenesis and serve as fluorescent transthyretin folding sensors. Chem Commun (Camb) (2013) 0.80
Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun (2016) 0.79
Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations. Protein Sci (2010) 0.79
Amyloid formation by human carboxypeptidase D transthyretin-like domain under physiological conditions. J Biol Chem (2014) 0.78
Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage. Biosci Rep (2015) 0.78
The effect of tafamidis on the QTc interval in healthy subjects. Br J Clin Pharmacol (2015) 0.78
Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case. Biochemistry (2014) 0.78
Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology. Am J Med (2015) 0.77
Partially Unfolded Forms of the Prion Protein Populated under Misfolding-promoting Conditions: CHARACTERIZATION BY HYDROGEN EXCHANGE MASS SPECTROMETRY AND NMR. J Biol Chem (2015) 0.77
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther (2016) 0.77
Structure-based analysis of A19D, a variant of transthyretin involved in familial amyloid cardiomyopathy. PLoS One (2013) 0.76
A New Folding Kinetic Mechanism for Human Transthyretin and the Influence of the Amyloidogenic V30M Mutation. Int J Mol Sci (2016) 0.75
Transthyretin Cardiac Amyloidosis in Black Americans. Circ Heart Fail (2016) 0.75
Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures. Theranostics (2016) 0.75
The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses. J Biol Chem (2014) 0.75
Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Sci Rep (2017) 0.75
A current pharmacologic agent versus the promise of next generation therapeutics to ameliorate protein misfolding and/or aggregation diseases. Curr Opin Chem Biol (2016) 0.75
Fluorotryptophan incorporation modulates the structure and stability of transthyretin in a site-specific manner. Biochemistry (2017) 0.75
sw ApoMb Amyloid Aggregation under Nondenaturing Conditions: The Role of Native Structure Stability. Biophys J (2017) 0.75
Protein misfolding, evolution and disease. Trends Biochem Sci (1999) 7.73
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature (1997) 5.47
Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold Des (1998) 4.10
Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med (1997) 3.65
The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry (1996) 3.42
Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol (1996) 3.20
Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry (1992) 3.19
Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A (1990) 2.87
A protein-folding reaction under kinetic control. Nature (1992) 2.82
Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol (2000) 2.47
Partially unfolded states of beta(2)-microglobulin and amyloid formation in vitro. Biochemistry (2000) 2.47
A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci U S A (1994) 2.27
Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein. Biochemistry (1999) 1.93
Trans-suppression of misfolding in an amyloid disease. Science (2001) 1.88
An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry (2001) 1.85
Folding of prion protein to its native alpha-helical conformation is under kinetic control. J Biol Chem (2001) 1.84
Unfolded conformations of alpha-lytic protease are more stable than its native state. Nature (1998) 1.75
A glimpse of a possible amyloidogenic intermediate of transthyretin. Nat Struct Biol (2000) 1.63
Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry (1995) 1.59
Transthyretin mutations in health and disease. Hum Mutat (1995) 1.58
The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry (1999) 1.57
Energetic landscape of alpha-lytic protease optimizes longevity through kinetic stability. Nature (2002) 1.47
The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci U S A (2001) 1.45
Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants. Biochemistry (1999) 1.44
Detection of two partially structured species in the folding process of the amyloidogenic protein beta 2-microglobulin. J Mol Biol (2001) 1.39
Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci (2001) 1.30
Genetic aspects of amyloidosis. Adv Hum Genet (1991) 1.28
Familial amyloid polyneuropathy: new developments in genetics and treatment. Curr Opin Neurol (1996) 1.20
Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy. Biochemistry (2001) 1.10
Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet (1994) 1.10
Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc Natl Acad Sci U S A (2001) 1.06
Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. J Mol Biol (2001) 0.97
The stability and folding process of amyloidogenic mutant human lysozymes. Eur J Biochem (2001) 0.89
Adapting proteostasis for disease intervention. Science (2008) 13.22
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Opposing activities protect against age-onset proteotoxicity. Science (2006) 5.85
Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem (2009) 5.23
Semen-derived amyloid fibrils drastically enhance HIV infection. Cell (2007) 5.23
Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell (2006) 5.01
Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature (2009) 4.68
Therapeutic approaches to protein-misfolding diseases. Nature (2003) 4.57
Functional amyloid--from bacteria to humans. Trends Biochem Sci (2007) 4.50
Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science (2011) 4.13
Functional amyloid formation within mammalian tissue. PLoS Biol (2006) 3.92
The renewal and differentiation of Isl1+ cardiovascular progenitors are controlled by a Wnt/beta-catenin pathway. Cell Stem Cell (2007) 3.54
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology (2012) 3.48
Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell (2008) 3.11
Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell (2009) 2.87
The biological and chemical basis for tissue-selective amyloid disease. Cell (2005) 2.76
Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A (2002) 2.71
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol (2009) 2.70
Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science (2003) 2.63
An experimental survey of the transition between two-state and downhill protein folding scenarios. Proc Natl Acad Sci U S A (2008) 2.57
Context-dependent contributions of backbone hydrogen bonding to beta-sheet folding energetics. Nature (2004) 2.44
Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet (2010) 2.41
Structure-function-folding relationship in a WW domain. Proc Natl Acad Sci U S A (2006) 2.28
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A (2012) 2.27
Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res (2005) 2.25
Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants. ACS Chem Biol (2006) 2.25
Tuning the free-energy landscape of a WW domain by temperature, mutation, and truncation. Proc Natl Acad Sci U S A (2003) 2.15
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A (2004) 2.14
Dependence of current and field driven depinning of domain walls on their structure and chirality in permalloy nanowires. Phys Rev Lett (2006) 2.11
The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension. Cardiovasc Res (2013) 2.08
Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry (2004) 2.08
Amyloid-β forms fibrils by nucleated conformational conversion of oligomers. Nat Chem Biol (2011) 2.08
Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep (2013) 1.87
An adaptable standard for protein export from the endoplasmic reticulum. Cell (2007) 1.86
ALS mutants of human superoxide dismutase form fibrous aggregates via framework destabilization. J Mol Biol (2003) 1.82
Complete genome sequence of Paenibacillus polymyxa SC2, a strain of plant growth-promoting Rhizobacterium with broad-spectrum antimicrobial activity. J Bacteriol (2010) 1.76
Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. Chem Biol (2004) 1.76
Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci U S A (2013) 1.73
Zipper-like interaction between proteins in adjacent daughter cells mediates protein localization. Genes Dev (2004) 1.72
Determinants for dephosphorylation of the RNA polymerase II C-terminal domain by Scp1. Mol Cell (2006) 1.71
The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol (2012) 1.70
Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol (2005) 1.68
Therapeutic strategies for human amyloid diseases. Nat Rev Drug Discov (2002) 1.63
Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol (2010) 1.62
Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci Transl Med (2011) 1.62
Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol (2006) 1.60
Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J Med Chem (2007) 1.58
Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.55
Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des (2008) 1.55
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol (2013) 1.54
Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem (2004) 1.54
The core trisaccharide of an N-linked glycoprotein intrinsically accelerates folding and enhances stability. Proc Natl Acad Sci U S A (2009) 1.54
Targeted conditional gene knockout in human embryonic stem cells. Cell Res (2010) 1.53
Amylin proprotein processing generates progressively more amyloidogenic peptides that initially sample the helical state. Biochemistry (2008) 1.51
Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest (2004) 1.50
Engineering a beta-sheet protein toward the folding speed limit. J Phys Chem B (2005) 1.49
Tubular graphite cones. Science (2003) 1.44
Oscillatory dependence of current-driven magnetic domain wall motion on current pulse length. Nature (2006) 1.42
Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol (2008) 1.42
Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis. Cold Spring Harb Perspect Biol (2011) 1.41
A fundamental protein property, thermodynamic stability, revealed solely from large-scale measurements of protein function. Proc Natl Acad Sci U S A (2012) 1.39
Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew Chem Int Ed Engl (2003) 1.39
Retracted Pathological dislocation of the hip due to coxotuberculosis in children: a 29-case report. J Orthop Surg Res (2014) 1.38
Localized thermodynamic coupling between hydrogen bonding and microenvironment polarity substantially stabilizes proteins. Nat Struct Mol Biol (2009) 1.37
D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry (2003) 1.36
Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid (2006) 1.34
The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry (2005) 1.32
The proteostasis boundary in misfolding diseases of membrane traffic. FEBS Lett (2009) 1.31
Heparin accelerates gelsolin amyloidogenesis. Biochemistry (2006) 1.31
Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J (2007) 1.29
N-terminal domains elicit formation of functional Pmel17 amyloid fibrils. J Biol Chem (2009) 1.28
Protein native-state stabilization by placing aromatic side chains in N-glycosylated reverse turns. Science (2011) 1.27
Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry (2005) 1.26
Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc Natl Acad Sci U S A (2003) 1.26
Toward assessing the position-dependent contributions of backbone hydrogen bonding to beta-sheet folding thermodynamics employing amide-to-ester perturbations. J Am Chem Soc (2004) 1.26
Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry (2008) 1.26
Endoplasmic reticulum Ca2+ increases enhance mutant glucocerebrosidase proteostasis. Nat Chem Biol (2010) 1.26
Toward quantification of protein backbone-backbone hydrogen bonding energies: An energetic analysis of an amide-to-ester mutation in an alpha-helix within a protein. Protein Sci (2008) 1.26
The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry (2007) 1.25
NMR solution structure of the isolated Apo Pin1 WW domain: comparison to the x-ray crystal structures of Pin1. Biopolymers (2002) 1.24